Lisa M McShane
Overview
Explore the profile of Lisa M McShane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
146
Citations
15199
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wolff A, McShane L, Allison K
N Engl J Med
. 2025 Feb;
392(8):829.
PMID: 39970411
No abstract available.
2.
Gouda M, Wei Z, Rodon J, Davies M, Janku F, Gray R, et al.
JCO Precis Oncol
. 2025 Feb;
9:e2400451.
PMID: 39913886
Purpose: Copanlisib, a pan-class phosphatidylinositol 3-kinase (PI3K) inhibitor with activity predominantly against the PI3K-delta and PI3K-alpha isoforms, has shown promising results in preclinical cancer models with PTEN loss. Herein, we...
3.
Zauderer M, Jegede O, Jackman D, Zwiebel J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400327.
PMID: 39693587
Purpose: The NCI-MATCH trial assigned patients with solid tumors, lymphomas, or multiple myeloma to targeted therapies on the basis of identified genetic alterations from tumor biopsies. In preclinical models, ()-inactivated...
4.
Gien L, Song Z, Poklepovic A, Collisson E, Zwiebel J, Gray R, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400514.
PMID: 39666929
Purpose: The NCI-MATCH study is a tumor-agnostic platform trial enrolling patients to targeted therapies on the basis of genomic alterations. Subprotocol V investigated sunitinib in patients with tumors harboring -...
5.
Kaluziak S, Codd E, Purohit R, Melli B, Kalyan P, Fordham J, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400493.
PMID: 39637335
Purpose: The National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) trial was implemented to identify actionable genetic alterations across cancer types and enroll patients accordingly onto treatment arms, irrespective of...
6.
McShane L, Harris L
J Natl Cancer Inst
. 2024 Nov;
117(1):6-8.
PMID: 39514678
No abstract available.
7.
OHara M, Jegede O, Dickson M, DeMichele A, Piekarz R, Gray R, et al.
Clin Cancer Res
. 2024 Oct;
31(1):56-64.
PMID: 39437014
Purpose: Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature of a variety of malignancies, and preclinical evidence suggests that inhibition of CDK4/6 is a plausible treatment strategy...
8.
Konate M, Krushkal J, Li M, Chen L, Kotliarov Y, Palmisano A, et al.
J Transl Med
. 2024 Aug;
22(1):733.
PMID: 39103840
Background: With poor prognosis and high mortality, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Standard of care therapies for PDAC have included gemcitabine for the past...
9.
Gettinger S, Song Z, Reckamp K, Moscow J, Gray R, Wang V, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2300725.
PMID: 38986051
Purpose: National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH) was a multicohort phase 2 trial that assigned patients with advanced pretreated cancers to molecularly targeted therapies on the basis of...
10.
Meric-Bernstam F, Lloyd M, Koc S, Evrard Y, McShane L, Lewis M, et al.
Mol Cancer Ther
. 2024 Apr;
23(7):924-938.
PMID: 38641411
Although patient-derived xenografts (PDX) are commonly used for preclinical modeling in cancer research, a standard approach to in vivo tumor growth analysis and assessment of antitumor activity is lacking, complicating...